Skip to main content
Onxeo logo

Onxeo — Investor Relations & Filings

Ticker · ALONX ISIN · FR0010095596 LEI · 96950018AS30IUG0V528 PA Manufacturing
Open in API
Filings indexed 661 across all filing types
Latest filing 2022-03-31 Regulatory Filings
Country FR France
Listing PA ALONX

About Onxeo

https://www.onxeo.com/

Valerio Therapeutics, formerly Onxeo, is a biotechnology company developing next-generation precision-guided therapies for complex and underserved diseases. The company's core technology is its proprietary V-Body platform, which is based on two fully synthetic single-domain antibody (sdAb) libraries. This platform is engineered to create advanced drug conjugates that enable deep tissue penetration and highly precise therapeutic delivery. By integrating innovative target identification, antibody engineering, and cutting-edge linker and payload technologies, Valerio Therapeutics aims to develop treatments with superior efficacy and target engagement. The company's strategy involves advancing its therapeutic candidates to key development milestones before pursuing strategic partnerships for co-development and out-licensing.

Recent filings

Filing Released Lang Actions
Informations privilégiées / Autres communiqués
Regulatory Filings Classification · 1% confidence The document is a press release dated March 31, 2022, announcing that Onxeo will present new preclinical data on its drug candidate AsiDNA™ at the AACR Annual Meeting 2022 (April 8-13, 2022). It details the content of the oral and poster presentations and includes quotes from management. Crucially, it also contains a section titled "Prochain communiqué financier: Les résultats annuels 2021 : le jeudi 7 avril 2022 (avant ouverture du marché)". This structure—announcing upcoming scientific data presentation and referencing a future financial report release—is characteristic of a general corporate update or press release that doesn't fit the specific definitions of 10-K, ER, or IR. Since it is a formal announcement about corporate activities (data presentation) and not a regulatory filing itself, it is best classified as a general Regulatory Filing (RNS) as a catch-all for non-standard announcements, or potentially an Investor Presentation (IP) if the focus was solely on the presentation materials, but here it is an announcement *about* the presentation. Given the context of scientific data release announcements, RNS is the most appropriate fallback if it's not a specific Investor Presentation (IP) or Earnings Release (ER). Since it is announcing scientific data to be presented at a conference, and not a formal financial report, RNS is the most suitable general regulatory announcement category.
2022-03-31 French
Inside Information / Other news releases
Regulatory Filings Classification · 1% confidence The document is a press release from Onxeo announcing the presentation of new preclinical data at the ESMO Targeted Anticancer Therapies Congress 2022. It details scientific findings, includes quotes from management, and provides links to the abstract and presentation. Crucially, it also contains a section titled 'Next financial press release: Full-year 2021 results: Friday, April 1st, 2022 (after market close)'. This structure—announcing scientific/operational news while simultaneously scheduling a future financial report release—is characteristic of an Earnings Release (ER) or a general corporate update that precedes a formal financial filing. Since the core content is scientific data presentation rather than the actual financial results themselves, and it is a press release format, it is best classified as an Earnings Release (ER) if it's a precursor to the main results announcement, or potentially a Regulatory Filing (RNS) if it's purely scientific news. Given the inclusion of the specific date for the 'Full-year 2021 results' announcement, this document functions as a pre-earnings update or a significant operational announcement often bundled with ER activity. However, since the primary focus is scientific data presentation and not the actual financial highlights (which are scheduled for April 1st), it is most accurately categorized as a general announcement or a scientific update. Since there is no specific category for 'Scientific Update' and it is not a transcript (CT), presentation (IP), or formal report (10-K/IR), the most appropriate general category for a significant, non-financial-specific press release is Regulatory Filings (RNS), as it disseminates material information to the market. Alternatively, if we interpret the announcement of future financial results as the key driver, ER might apply, but the content is overwhelmingly scientific. I will lean towards RNS as the most fitting general regulatory disclosure for material, non-financial-specific news.
2022-03-09 English
Informations privilégiées / Autres communiqués
Regulatory Filings Classification · 1% confidence The document is a press release from Onxeo S.A. dated March 9, 2021 (though it references a conference in March 2022), announcing the presentation of new preclinical data at the ESMO Targeted Anticancer Therapies congress. It details scientific findings regarding the drug candidate AsiDNA™ and its combination with PARP inhibitors. This type of announcement, focusing on scientific updates, clinical trial progress, or presentation of data at medical conferences, is typically classified as an Investor Presentation (IP) if it were a deck, or often falls under a general regulatory/investor communication category. Since it is a detailed announcement of scientific progress and potential therapeutic relevance, and not a formal financial report (like 10-K or IR), nor a simple announcement of a report's release (RPA), it best fits the Investor Presentation (IP) category, as these press releases often serve the same function of informing investors about strategic scientific developments. It is not a Call Transcript (CT), Earnings Release (ER), or a formal financial filing. Given the focus on presenting data that supports the company's pipeline value, IP is the most appropriate fit among the specialized codes.
2022-03-09 French
Inside Information / Other news releases
Report Publication Announcement Classification · 1% confidence The document is titled "Onxeo Announces its Financial Agenda for 2022" and explicitly lists dates for 'Full-year 2021 results', 'Shareholders' general meeting', and 'Half-year 2022 results'. This is a press release announcing future corporate events, specifically the schedule for financial reporting and the AGM. Since the document is short (under 5,000 characters) and its primary function is to announce *when* reports/meetings will occur rather than being the report itself, it fits the definition of a Report Publication Announcement (RPA). It is not the full 10-K, IR, or the AGM material itself, but the announcement of their schedule.
2022-01-13 English
Informations privilégiées / Autres communiqués
Report Publication Announcement Classification · 1% confidence The document is titled "Onxeo annonce son calendrier financier 2022" (Onxeo announces its 2022 financial calendar) and explicitly lists future dates for key corporate events: Annual Results 2021, Annual General Meeting (AGM), and H1 2022 Results. This document is an announcement detailing the schedule for future corporate reports and meetings, rather than being one of the reports itself (like 10-K, ER, or IR). Since it is an announcement about the publication schedule of other reports, it fits best under the category for announcing the release of reports, which is Report Publication Announcement (RPA). The document length (5344 chars) is substantial enough that it's more than just a brief notice, but its core function is scheduling future events, making RPA the most precise fit over the general fallback RNS.
2022-01-13 French
Acquisition or disposal of the issuer's own shares / Information relating to the liquidity contract
Regulatory Filings Classification · 1% confidence The document is explicitly titled "PRESS RELEASE" and details the summary of a "liquidity contract" between the company (ONXEO) and a financial intermediary (Kepler Cheuvreux), reporting share and cash balances, and transaction volumes for a specific period (ending December 31st, 2021). This type of disclosure, often mandated by financial regulators (like the AMF mentioned in the text) regarding market making or liquidity provision activities, is a specific type of regulatory announcement. It is not a full financial report (10-K or IR), an earnings release (ER), a management discussion (MDA), or a proxy statement (DEF 14A/PSI). Since it is a specific regulatory disclosure concerning market activity and is presented as a press release, it fits best under the general category for regulatory announcements that don't fit other specific codes. While it relates to capital management, it is not a financing event (CAP) or a share repurchase (POS), but rather a routine disclosure about market stability mechanisms. Therefore, the most appropriate classification is Regulatory Filings (RNS) as a catch-all for specific, non-standard regulatory disclosures.
2022-01-07 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.